Neuroendocrine Tumor Drug Market Report

Global and Region Neuroendocrine Tumor Drug Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 03, 2022
  • PAGES：168
  • REPORT CODE：GMM1020875
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Neuroendocrine Tumor Drug market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Neuroendocrine Tumor Drugmarket, defines the market attractiveness level of Neuroendocrine Tumor Drug market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Neuroendocrine Tumor Drug industry, describes the types of Neuroendocrine Tumor Drug market, the applications of major players and the market size, and deeply analyzes the current situation of the global Neuroendocrine Tumor Drug market and the development prospects and opportunities of Neuroendocrine Tumor Drug industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Neuroendocrine Tumor Drug market in Chapter 13.

    By Player:

    • Exelixis, Inc

    • OctreoPharm Sciences GmbH

    • INVENT Pharmaceuticals, Inc

    • Intezyne, Inc

    • Novartis AG

    • Northwest Biotherapeutics, Inc

    • Lexicon Pharmaceuticals, Inc

    • Hutchison MediPharma Limited

    • MolMed SpA

    • Midatech Pharma Plc

    • Jiangsu Hengrui Medicine Co, Ltd

    • OXiGENE, Inc

    • Karyopharm Therapeutics, Inc

    • Foresee Pharmaceuticals, LLC

    • Millennium Pharmaceuticals, Inc

    • Ipsen SA

    • Eisai

    By Type:

    • mTOR Protein Inhibitors

    • Tyrosine Kinase 3 Inhibitors

    • Somatostatin Receptor Antagonists

    • Growth Hormone Releasing Factor Antagonists

    • Somatostatin Receptor Agonists

    • Others

    By End-User:

    • Hospitals

    • Clinics

    • Others

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Neuroendocrine Tumor Drug Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Neuroendocrine Tumor Drug Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Neuroendocrine Tumor Drug Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Neuroendocrine Tumor Drug Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Neuroendocrine Tumor Drug Market Analysis and Outlook to 2022

    • 7.1 Global Neuroendocrine Tumor Drug Consumption (2017-2022)

    • 7.2 United States Neuroendocrine Tumor Drug Consumption (2017-2022)

    • 7.3 Europe Neuroendocrine Tumor Drug Consumption (2017-2022)

    • 7.4 China Neuroendocrine Tumor Drug Consumption (2017-2022)

    • 7.5 Japan Neuroendocrine Tumor Drug Consumption (2017-2022)

    • 7.6 India Neuroendocrine Tumor Drug Consumption (2017-2022)

    • 7.7 South Korea Neuroendocrine Tumor Drug Consumption (2017-2022)

    8 Region and Country-wise Neuroendocrine Tumor Drug Market Analysis and Outlook to 2028

    • 8.1 Global Neuroendocrine Tumor Drug Consumption Forecast (2022-2028)

    • 8.2 United States Neuroendocrine Tumor Drug Consumption Forecast (2022-2028)

    • 8.3 Europe Neuroendocrine Tumor Drug Consumption Forecast (2022-2028)

    • 8.4 China Neuroendocrine Tumor Drug Consumption Forecast (2022-2028)

    • 8.5 Japan Neuroendocrine Tumor Drug Consumption Forecast (2022-2028)

    • 8.6 India Neuroendocrine Tumor Drug Consumption Forecast (2022-2028)

    • 8.7 South Korea Neuroendocrine Tumor Drug Consumption Forecast (2022-2028)

    9 Global Neuroendocrine Tumor Drug Market Outlook by Types and Applications to 2022

    • 9.1 Global Neuroendocrine Tumor Drug Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global mTOR Protein Inhibitors Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Tyrosine Kinase 3 Inhibitors Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Somatostatin Receptor Antagonists Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Growth Hormone Releasing Factor Antagonists Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global Somatostatin Receptor Agonists Consumption and Growth Rate (2017-2022)

      • 9.1.6 Global Others Consumption and Growth Rate (2017-2022)

    • 9.2 Global Neuroendocrine Tumor Drug Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Others Consumption and Growth Rate (2017-2022)

    10 Global Neuroendocrine Tumor Drug Market Outlook by Types and Applications to 2028

    • 10.1 Global Neuroendocrine Tumor Drug Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global mTOR Protein Inhibitors Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Tyrosine Kinase 3 Inhibitors Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Somatostatin Receptor Antagonists Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Growth Hormone Releasing Factor Antagonists Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.5 Global Somatostatin Receptor Agonists Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.6 Global Others Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Neuroendocrine Tumor Drug Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)

    11 Global Neuroendocrine Tumor Drug Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Neuroendocrine Tumor Drug Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Neuroendocrine Tumor Drug Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Neuroendocrine Tumor Drug Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Neuroendocrine Tumor Drug Market Competitive Analysis

    • 14.1 Exelixis, Inc

      • 14.1.1 Exelixis, Inc Company Details

      • 14.1.2 Exelixis, Inc Neuroendocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Exelixis, Inc Neuroendocrine Tumor Drug Product and Service

    • 14.2 OctreoPharm Sciences GmbH

      • 14.2.1 OctreoPharm Sciences GmbH Company Details

      • 14.2.2 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Product and Service

    • 14.3 INVENT Pharmaceuticals, Inc

      • 14.3.1 INVENT Pharmaceuticals, Inc Company Details

      • 14.3.2 INVENT Pharmaceuticals, Inc Neuroendocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 INVENT Pharmaceuticals, Inc Neuroendocrine Tumor Drug Product and Service

    • 14.4 Intezyne, Inc

      • 14.4.1 Intezyne, Inc Company Details

      • 14.4.2 Intezyne, Inc Neuroendocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Intezyne, Inc Neuroendocrine Tumor Drug Product and Service

    • 14.5 Novartis AG

      • 14.5.1 Novartis AG Company Details

      • 14.5.2 Novartis AG Neuroendocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Novartis AG Neuroendocrine Tumor Drug Product and Service

    • 14.6 Northwest Biotherapeutics, Inc

      • 14.6.1 Northwest Biotherapeutics, Inc Company Details

      • 14.6.2 Northwest Biotherapeutics, Inc Neuroendocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Northwest Biotherapeutics, Inc Neuroendocrine Tumor Drug Product and Service

    • 14.7 Lexicon Pharmaceuticals, Inc

      • 14.7.1 Lexicon Pharmaceuticals, Inc Company Details

      • 14.7.2 Lexicon Pharmaceuticals, Inc Neuroendocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Lexicon Pharmaceuticals, Inc Neuroendocrine Tumor Drug Product and Service

    • 14.8 Hutchison MediPharma Limited

      • 14.8.1 Hutchison MediPharma Limited Company Details

      • 14.8.2 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Product and Service

    • 14.9 MolMed SpA

      • 14.9.1 MolMed SpA Company Details

      • 14.9.2 MolMed SpA Neuroendocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 MolMed SpA Neuroendocrine Tumor Drug Product and Service

    • 14.10 Midatech Pharma Plc

      • 14.10.1 Midatech Pharma Plc Company Details

      • 14.10.2 Midatech Pharma Plc Neuroendocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Midatech Pharma Plc Neuroendocrine Tumor Drug Product and Service

    • 14.11 Jiangsu Hengrui Medicine Co, Ltd

      • 14.11.1 Jiangsu Hengrui Medicine Co, Ltd Company Details

      • 14.11.2 Jiangsu Hengrui Medicine Co, Ltd Neuroendocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 Jiangsu Hengrui Medicine Co, Ltd Neuroendocrine Tumor Drug Product and Service

    • 14.12 OXiGENE, Inc

      • 14.12.1 OXiGENE, Inc Company Details

      • 14.12.2 OXiGENE, Inc Neuroendocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 OXiGENE, Inc Neuroendocrine Tumor Drug Product and Service

    • 14.13 Karyopharm Therapeutics, Inc

      • 14.13.1 Karyopharm Therapeutics, Inc Company Details

      • 14.13.2 Karyopharm Therapeutics, Inc Neuroendocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.13.3 Karyopharm Therapeutics, Inc Neuroendocrine Tumor Drug Product and Service

    • 14.14 Foresee Pharmaceuticals, LLC

      • 14.14.1 Foresee Pharmaceuticals, LLC Company Details

      • 14.14.2 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.14.3 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Product and Service

    • 14.15 Millennium Pharmaceuticals, Inc

      • 14.15.1 Millennium Pharmaceuticals, Inc Company Details

      • 14.15.2 Millennium Pharmaceuticals, Inc Neuroendocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.15.3 Millennium Pharmaceuticals, Inc Neuroendocrine Tumor Drug Product and Service

    • 14.16 Ipsen SA

      • 14.16.1 Ipsen SA Company Details

      • 14.16.2 Ipsen SA Neuroendocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.16.3 Ipsen SA Neuroendocrine Tumor Drug Product and Service

    • 14.17 Eisai

      • 14.17.1 Eisai Company Details

      • 14.17.2 Eisai Neuroendocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.17.3 Eisai Neuroendocrine Tumor Drug Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Neuroendocrine Tumor Drug

    • Figure Neuroendocrine Tumor Drug Picture

    • Table Global Neuroendocrine Tumor Drug Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Neuroendocrine Tumor Drug Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Neuroendocrine Tumor Drug Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Neuroendocrine Tumor Drug Consumption by Country (2017-2022)

    • Figure United States Neuroendocrine Tumor Drug Consumption and Growth Rate (2017-2022)

    • Table Europe Neuroendocrine Tumor Drug Consumption and Growth Rate (2017-2022)

    • Figure China Neuroendocrine Tumor Drug Consumption and Growth Rate (2017-2022)

    • Figure Japan Neuroendocrine Tumor Drug Consumption and Growth Rate (2017-2022)

    • Figure India Neuroendocrine Tumor Drug Consumption and Growth Rate (2017-2022)

    • Figure South Korea Neuroendocrine Tumor Drug Consumption and Growth Rate (2017-2022)

    • Figure Global Neuroendocrine Tumor Drug Consumption Forecast by Country (2022-2028)

    • Figure United States Neuroendocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Neuroendocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Neuroendocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Neuroendocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Neuroendocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Neuroendocrine Tumor Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global mTOR Protein Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Global Tyrosine Kinase 3 Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Global Somatostatin Receptor Antagonists Consumption and Growth Rate (2017-2022)

    • Figure Global Growth Hormone Releasing Factor Antagonists Consumption and Growth Rate (2017-2022)

    • Figure Global Somatostatin Receptor Agonists Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Hospitals Consumption and Growth Rate (2017-2022)

    • Figure Global Clinics Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global mTOR Protein Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Tyrosine Kinase 3 Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Somatostatin Receptor Antagonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Growth Hormone Releasing Factor Antagonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Somatostatin Receptor Agonists Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Neuroendocrine Tumor Drug Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Neuroendocrine Tumor Drug Export by Region (Top 5 Countries) (2017-2028)

    • Table Exelixis, Inc (Foundation Year, Company Profile and etc.)

    • Table Exelixis, Inc Neuroendocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Exelixis, Inc Neuroendocrine Tumor Drug Product and Service

    • Table OctreoPharm Sciences GmbH (Foundation Year, Company Profile and etc.)

    • Table OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Product and Service

    • Table INVENT Pharmaceuticals, Inc (Foundation Year, Company Profile and etc.)

    • Table INVENT Pharmaceuticals, Inc Neuroendocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table INVENT Pharmaceuticals, Inc Neuroendocrine Tumor Drug Product and Service

    • Table Intezyne, Inc (Foundation Year, Company Profile and etc.)

    • Table Intezyne, Inc Neuroendocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Intezyne, Inc Neuroendocrine Tumor Drug Product and Service

    • Table Novartis AG (Foundation Year, Company Profile and etc.)

    • Table Novartis AG Neuroendocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novartis AG Neuroendocrine Tumor Drug Product and Service

    • Table Northwest Biotherapeutics, Inc (Foundation Year, Company Profile and etc.)

    • Table Northwest Biotherapeutics, Inc Neuroendocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Northwest Biotherapeutics, Inc Neuroendocrine Tumor Drug Product and Service

    • Table Lexicon Pharmaceuticals, Inc (Foundation Year, Company Profile and etc.)

    • Table Lexicon Pharmaceuticals, Inc Neuroendocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Lexicon Pharmaceuticals, Inc Neuroendocrine Tumor Drug Product and Service

    • Table Hutchison MediPharma Limited (Foundation Year, Company Profile and etc.)

    • Table Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Hutchison MediPharma Limited Neuroendocrine Tumor Drug Product and Service

    • Table MolMed SpA (Foundation Year, Company Profile and etc.)

    • Table MolMed SpA Neuroendocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table MolMed SpA Neuroendocrine Tumor Drug Product and Service

    • Table Midatech Pharma Plc (Foundation Year, Company Profile and etc.)

    • Table Midatech Pharma Plc Neuroendocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Midatech Pharma Plc Neuroendocrine Tumor Drug Product and Service

    • Table Jiangsu Hengrui Medicine Co, Ltd (Foundation Year, Company Profile and etc.)

    • Table Jiangsu Hengrui Medicine Co, Ltd Neuroendocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Jiangsu Hengrui Medicine Co, Ltd Neuroendocrine Tumor Drug Product and Service

    • Table OXiGENE, Inc (Foundation Year, Company Profile and etc.)

    • Table OXiGENE, Inc Neuroendocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table OXiGENE, Inc Neuroendocrine Tumor Drug Product and Service

    • Table Karyopharm Therapeutics, Inc (Foundation Year, Company Profile and etc.)

    • Table Karyopharm Therapeutics, Inc Neuroendocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Karyopharm Therapeutics, Inc Neuroendocrine Tumor Drug Product and Service

    • Table Foresee Pharmaceuticals, LLC (Foundation Year, Company Profile and etc.)

    • Table Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Product and Service

    • Table Millennium Pharmaceuticals, Inc (Foundation Year, Company Profile and etc.)

    • Table Millennium Pharmaceuticals, Inc Neuroendocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Millennium Pharmaceuticals, Inc Neuroendocrine Tumor Drug Product and Service

    • Table Ipsen SA (Foundation Year, Company Profile and etc.)

    • Table Ipsen SA Neuroendocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Ipsen SA Neuroendocrine Tumor Drug Product and Service

    • Table Eisai (Foundation Year, Company Profile and etc.)

    • Table Eisai Neuroendocrine Tumor Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Eisai Neuroendocrine Tumor Drug Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US